Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study

Study limitation reported by the research below: “Median follow-up was up to 2 years; longer-term trajectories of biomarkers such as TREM2 and NPTXR remain unknown.”